Clinical Trial Update: Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing apatinib and etoposide capsule versus weekly paclitaxel in platinum-resistant ovarian cancer is ongoing (status unknown).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• apatinib and etoposide capsule

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Ovarian Cancer | Phase 3 | Status: UNKNOWN